Turn Therapeutics updates on GX-03 phase 2 eczema trial: 25% enrolled, topline 2026; $85M GEM facility

Turn Therapeutics Inc.

Phase 2 trial of GX-03 (topical IL-36/IL-31 inhibitor) for moderate-severe eczema: ~25% of targeted sample completed, no safety concerns; topline results expected in 2026.
Company completed dilution-sparing direct listing with $85M GEM Global Yield on-demand financing vehicle to reduce reliance on future equity offerings.
Intranasal vaccine initiative advancing; in-vivo studies scheduled to commence in Q4 2025.
Shareholder webinar held today, October 22, 2025 at 2:00 PM ET to review milestones and capital strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.